Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levalbuterol Tartrate HFA MDI for Prevention of EIB
NCT00268723Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2005
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exercise-induced bronchospasm (EIB) comparing Levalbuterol tartrate HFA MDI with Placebo MDI (2 arms). Primary endpoint: maximum percent FEV1 decrease from visit postdose/prechallenge. Started Dec 2005; status: completed.
02
Drugs
levalbuterol
03
Conditions
exercise-induced bronchospasm (EIB)
Beyond the preview
Go deeper on NCT00268723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268723.